NasdaqGM - Delayed Quote USD

Carisma Therapeutics, Inc. (CARM)

1.4600 -0.0200 (-1.35%)
At close: May 14 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Steven Kelly President, CEO & Director 786.91k -- 1965
Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD Co-Founder & Chief Scientific Officer 525.43k -- 1990
Mr. Richard S. Morris CPA CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. 584.85k -- 1974
Dr. Saar Gill M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board -- -- --
Dr. Daniel J. Cushing FCP, Ph.D. Chief Technology & Development Officer -- -- --
Mr. Eric H. Siegel J.D., MBA General Counsel & Corporate Secretary -- -- 1965
Ms. Terry Shields Senior Vice President of Human Resources -- -- --
Mr. Tom Wilton Chief Business Officer -- -- 1974
Dr. Eugene P. Kennedy F.A.C.S., M.D. Chief Medical Officer -- -- 1969

Carisma Therapeutics, Inc.

3675 Market Street
Suite 200
Philadelphia, PA 19104
United States
267-491-6422 https://www.carismatx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
107

Description

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Carisma Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 08, 2024 - Aug 12, 2024
Carisma Therapeutics, Inc. Earnings Call

Related Tickers

IPSC Century Therapeutics, Inc.
3.1500
+5.00%
 
VOR Vor Biopharma Inc.
1.6800
-1.18%
 
PRQR ProQR Therapeutics N.V.
1.9850
+0.25%
 
NGNE Neurogene Inc.
31.55
+2.97%
 
RNAC Cartesian Therapeutics, Inc.
24.75
+15.38%
 
ERAS Erasca, Inc.
1.8600
-2.11%
 
UNCY Unicycive Therapeutics, Inc.
1.0900
0.00%
 
BOLT Bolt Biotherapeutics, Inc.
1.3200
-0.75%
 
KZR Kezar Life Sciences, Inc.
0.7895
+5.62%
 
RLYB Rallybio Corporation
1.8400
+3.37%